Harbingers For IPF Drug Development

Roche’s decision to discontinue a Phase III program in idiopathic pulmonary fibrosis was the latest of several recent late-stage clinical failures, emblematic of the difficulty in finding new approaches to treat the disease.

lung illustration

The near- and intermediate-term landscape for idiopathic pulmonary fibrosis (IPF) drug development shifted when, as part of its FY22 financial update in February,Roche Holding AGdisclosed that it was discontinuing development of the Phase III candidate PRM-151 (recombinant human pentraxin-2), the lead compound it acquired when it bought Promedior Inc. in 2019. [See Deal]

“With one less Phase III program recruiting patients and one less potential competitor in the treatment landscape, we see potential...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

More from Market Intelligence

More from In Vivo